Efficacy and safety of gefitinib or docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who had failed previous platinum-based first-line chemotherapy.
- Author:
Yan SUN
1
;
Yi-long WU
;
Long-yun LI
;
Mei-lin LIAO
;
Guo-liang JIANG
;
Edward S KIM
;
Jean-yves DOUILLARD
;
Tsveta MILENKOVA
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Antineoplastic Agents; adverse effects; therapeutic use; Carcinoma, Non-Small-Cell Lung; drug therapy; pathology; Diarrhea; chemically induced; Disease-Free Survival; Exanthema; chemically induced; Female; Humans; Lung Neoplasms; drug therapy; pathology; Male; Neoplasm Staging; Neutropenia; chemically induced; Platinum; therapeutic use; Quality of Life; Quinazolines; adverse effects; therapeutic use; Randomized Controlled Trials as Topic; Remission Induction; Retrospective Studies; Survival Rate; Taxoids; adverse effects; therapeutic use
- From: Chinese Journal of Oncology 2011;33(5):377-380
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo compare the efficacy and safety of gefitinib or docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who had failed previous platinum-based first-line chemotherapy.
METHODSWe retrospectively reviewed 222 Chinese NSCLC patients in the subgroup of INTEREST (gefitinib versus docetaxel in previously treated non-small cell lung cancer) study. Survival analysis was evaluated by Kaplan-Meier method, and Functional Assessment of Cancer Therapy-Lung (FACT-L) was used to compare the quality of life between gefitinib group and docetaxel group.
RESULTSA total of 222 patients were analyzed in this subgroup study. 107 patients were treated with gefitinib, and 115 patients treated with docetaxel. There were all balanced between the two groups in terms of sex, age, staging and pathology in patient characteristics. The median overall survival in the two groups was similar (11 months in the gefitinib group vs. 14.0 months in the docetaxel group, P = 0.783). The progression-free survival (PFS) was also similar between the two groups (median PFS: 3.4 months in gefitinib group vs. 3.8 months in docetaxel group, P = 0.214). The response rate in gefitinib group was significantly higher than that in the docetaxel group (21.9% vs. 9.1%, P = 0.016).
CONCLUSIONThe efficacy of gefitinib is similar with that of docetaxel in pretreated patients with locally advanced or metastatic NSCLC, however, gefitinib is more favorable in the tolerance and quality of life improvement.
